home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2783.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
2KB
|
35 lines
Document 2783
DOCN M94A2783
TI A phytopharmaceutical with potential for delaying HIV disease
progression.
DT 9412
AU Sawyer RC; Greenspan H; Torigian PC; Pharmakon USA, NY, NY 10004.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):226 (abstract no. PB0333). Unique
Identifier : AIDSLINE ICA10/94369792
AB OBJECTIVE: To evaluate the effects of a phytopharmaceutical product on
CD4 counts weight and hemoglobin levels in HIV infected patients.
METHODS: Perthon is a combination of 11 medicinal plants which is
proposed to have immunostimulatory properties. Patients took Perthon on
a daily basis and were evaluated periodically for disease progression.
RESULTS: Twelve patients in Australia took open label Perthon for an
average 16 months. Patients were monitored for changes in CD4/CD8 ratio,
weight and laboratory values. TABULAR DATA, SEE ABSTRACT VOLUME. Only 2
of 12 patients had pretreatment CD4/CD8 > or = 1.0. Following Perthon, 7
of 12 patients had a CD4/CD8 > or = 1.0. An additional 2 patients had
ratios of 0.85 and 0.94. Use of the product was also associated with
increases in Hgb and weight with anecdotal reports of improved appetite,
higher energy levels and lessening of lethargic feelings. Only minor
side effects of rash and body odor were reported. CONCLUSION AND
DISCUSSION: Use of Perthon in HIV infected patients appears to be safe
and resulted in statistically significant increases in CD4/CD8, weight
and Hgb. A Phase II trial in the United States is planned.
DE Adjuvants, Immunologic/PHARMACOLOGY/*THERAPEUTIC USE Drug Combinations
Hemoglobins/ANALYSIS Human HIV Infections/BLOOD/*THERAPY Leukocyte
Count/DRUG EFFECTS Plant Extracts/PHARMACOLOGY/*THERAPEUTIC USE
*Plants, Medicinal Treatment Outcome T4 Lymphocytes Weight Gain/DRUG
EFFECTS CLINICAL TRIAL MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).